Two medicines, side by side
Bisoprolol vs telmisartan
Bisoprolol and telmisartan are both labeled for high blood pressure. Drugs@FDA records approvals of bisoprolol since 1992 and of telmisartan since 1998. Pharmacies paid $0.114 per bisoprolol fumarate 5 mg tablet and $0.106 per telmisartan 20 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, bisoprolol is a beta-adrenergic blocker and telmisartan an angiotensin 2 receptor blocker.
Check it at the source: the bisoprolol FDA label on DailyMed (effective March 11, 2026); the telmisartan FDA label on DailyMed (effective May 29, 2026).
Highlights of the bisoprolol record
Bisoprolol (Zebeta) · label of March 11, 2026
Used for
From the label: indicationsBisoprolol fumarate tablets are indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.
On the market
- Earliest approval on file
- July 31, 1992
- Generic labelers
- 24 labelers
- Pharmacy cost
- $0.114 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 2
Highlights of the telmisartan record
Telmisartan (Micardis) · label of May 29, 2026
FETAL TOXICITY When pregnancy is detected, discontinue telmisartan as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warnings.
Used for
From the label: indicationsTelmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1) 1.1 Hypertension Telmisartan is indicated for the treatment of hypertension, to lower blood pressure. […]
On the market
- Earliest approval on file
- November 10, 1998
- Generic labelers
- 28 labelers
- Pharmacy cost
- $0.106 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 3
Source: FDA drug labels via openFDA (Bisoprolol label of March 11, 2026, Telmisartan label of May 29, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do bisoprolol and telmisartan differ on the record?
In FDA's classes, bisoprolol is a beta-adrenergic blocker and telmisartan an angiotensin 2 receptor blocker.
Half-life, in each label's words: Bisoprolol, “The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of …”; Telmisartan, “Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.”
Only the telmisartan label carries a boxed warning.
Generics: bisoprolol since 2000; telmisartan since 2014 (Drugs@FDA).
| Bisoprolol | Telmisartan | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure, Heart attack and coronary artery disease |
| Pharmacologic class | beta-Adrenergic Blocker | Angiotensin 2 Receptor Blocker |
| How it works (label) | n/a | Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). |
| Half-life (label) | The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population. | Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours. |
| Earliest approval on file (Drugs@FDA) | July 31, 1992 | November 10, 1998 |
| First generic approved | November 16, 2000 | January 8, 2014 |
| Generic labelers (NDC) | 24 labelers | 28 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.114 per tablet (Bisoprolol fumarate 5 mg tablet) | $0.106 per tablet (Telmisartan 20 mg tablet) |
| 12-month price change | -39% | -4% |
| Boxed warning | No | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 2 | 3 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 135,060 | 17,745 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to bisoprolol
- every medicine labeled for the same conditions